Acumen Pharmaceuticals (ABOS) Other financing activities (2021 - 2026)

Acumen Pharmaceuticals (ABOS) has 5 years of Other financing activities data on file, last reported at $145000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities changed N/A year-over-year to $145000.0; the trailing twelve-month figure through Mar 2026 stood at $184000.0 (changed N/A YoY), and the FY2025 full-year result was $39000.0, changed N/A from the prior year.
• Other financing activities climbed to $145000.0 in Q1 2026, from $2000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $325000.0 in Q3 2023 to a low of -$19000.0 in Q4 2022.
• A 4-year average of $91857.1 and a median of $37000.0 in 2025 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities plunged 103.1% in 2022 and surged 16150.0% in 2023, its largest moves.
• Tracing ABOS's Other financing activities over 4 years: stood at -$19000.0 in 2022, then surged by 894.74% to $151000.0 in 2023, then sank by 98.68% to $2000.0 in 2025, then surged by 7150.0% to $145000.0 in 2026.
• Business Quant data shows ABOS's Other financing activities at $145000.0 in Q1 2026, $2000.0 in Q4 2025, and $37000.0 in Q2 2025.